Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2011 | 1 |
2012 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Complexities of TGF-β targeted cancer therapy.
Int J Biol Sci. 2012;8(7):964-78. doi: 10.7150/ijbs.4564. Epub 2012 Jul 12.
Int J Biol Sci. 2012.
PMID: 22811618
Free PMC article.
Review.
This review will describe pre-clinical and clinical data of four major classes of TGF-beta inhibitor, namely i) ligand traps, ii) antisense oligonucleotides, iii) receptor kinase inhibitors and iv) peptide aptamers. Long term dosing strategies with TGF-beta inhibitors may …
This review will describe pre-clinical and clinical data of four major classes of TGF-beta inhibitor, namely i) ligand traps, ii) antisense …
MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles.
Daldrup-Link HE, Golovko D, Ruffell B, Denardo DG, Castaneda R, Ansari C, Rao J, Tikhomirov GA, Wendland MF, Corot C, Coussens LM.
Daldrup-Link HE, et al.
Clin Cancer Res. 2011 Sep 1;17(17):5695-704. doi: 10.1158/1078-0432.CCR-10-3420. Epub 2011 Jul 26.
Clin Cancer Res. 2011.
PMID: 21791632
Free PMC article.
CONCLUSION: These data indicate that tumor enhancement with clinically applicable iron oxide nanoparticles may serve as a new biomarker for long-term prognosis, related treatment decisions, and the evaluation of new immune-targeted therapies....
CONCLUSION: These data indicate that tumor enhancement with clinically applicable iron oxide nanoparticles may serve as a new biomarker for …
Item in Clipboard
Cite
Cite